SCHEMBL7778696

SCHEMBL7778696

O=C(NCCN1CC2CC(c3ccc4ccccc4c3)C2C1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLD1 Q13393 2/20 0.50
HTR1A P08908 9/20 0.49
CYP1A2 P05177 2/20 0.48
CYP2D6 P10635 2/20 0.48
CYP2C19 P33261 2/20 0.48
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HSP90AA1 P07900 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42
PKM P14618 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
DRD3 P35462 1/20 0.42
MCHR1 Q99705 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7778688 0.93 PLD1 (0.50) PLD1HTR1ACYP1A2CYP2D6CYP2C19
SCHEMBL7817609 0.92 HTR1A (0.46) PLD1HTR1ACYP1A2CYP2D6CYP2C19
SCHEMBL7781173 0.89 PLD1 (0.47) PLD1HTR1ACYP1A2CYP2D6CYP2C19
SCHEMBL7778722 0.88 KDM1A (0.50) PLD1SLC6A2SLC6A4
SCHEMBL7781216 0.86 HPGD (0.52) PLD1HTR1ACYP1A2CYP2D6CYP2C19
SCHEMBL7774077 0.85 PLD1 (0.53) PLD1HTR1ANPC1ALDH1A1RAB9A
SCHEMBL7814210 0.81 HTR1A (0.43) PLD1HTR1ACYP1A2CYP2D6CYP2C19
SCHEMBL7781191 0.81 KDM4E (0.52) HTR1ASLC6A2SLC6A4NPC1ALDH1A1
SCHEMBL7817813 0.81 HTR2C (0.49) PLD1HTR1ADRD3DRD2
SCHEMBL8989699 0.81 PLD1 (0.56) PLD1HTR1ANPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1133293-A1 USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM BASF AKTIENGESELLSCHAFT (DE) 2001-09-19 EP disclosed
EP-0775113-B1 N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USEFUL AS NEUROLEPTICS BASF AG (DE) 2001-04-11 EP disclosed
WO-2000030639-A1 USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM BASF AKTIENGESELLSCHAFT (DE) 2000-06-02 WO disclosed
EP-0775113-A1 N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USEFUL AS NEUROLEPTICS BASF AKTIENGESELLSCHAFT (DE) 1997-05-28 EP disclosed
WO-1996004245-A1 N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USEFUL AS NEUROLEPTICS BASF AKTIENGESELLSCHAFT (DE) 1996-02-15 WO disclosed